ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
4.360
+0.065 (1.51%)
At close: Oct 7, 2026, 4:00 PM EDT
4.370
+0.010 (0.23%)
Pre-market: Oct 8, 2026, 4:01 AM EDT
ARS Pharmaceuticals Revenue
ARS Pharmaceuticals had revenue of $33.66M in the quarter ending June 30, 2026, with 114.15% growth. This brings the company's revenue in the last twelve months to $116.93M, up 4.08% year-over-year. In the year 2025, ARS Pharmaceuticals had annual revenue of $84.28M, down -5.46%. That makes ARS Pharmaceuticals the 21,447th largest company in the world by revenue and 3,201st in the United States.
Revenue (ttm)
$116.93M
Revenue Growth
+4.08%
P/S Ratio
3.71
Revenue / Employee
$584,635
Employees
200
Market Cap
433.59M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 84.28M | -4.87M | -5.46% |
| Dec 31, 2024 | 89.15M | 89.12M | 297,063.33% |
| Dec 31, 2023 | 30.00K | -1.29M | -97.72% |
| Dec 31, 2022 | 1.32M | -4.19M | -76.10% |
| Dec 31, 2021 | 5.51M | -12.33M | -69.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Assembly Biosciences | 74.85M |
| Prothena Corporation | 54.53M |
| Editas Medicine | 47.01M |
| Capricor Therapeutics | 11.13M |
| YD Bio | 1.24M |
| Entera Bio | 42.00K |
SPRY News
- 14 days ago - Kaplan Fox Reminds ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors with Significant Losses to Seek a Leadership Role Before Deadline on October 5, 2026 - GlobeNewsWire
- 15 days ago - Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (SPRY) to Act Ahead of the Lead Plaintiff Deadline on October 5, 2026 - Newsfile Corp
- 19 days ago - Kaplan Fox Alerts ARS Pharmaceuticals Inc. (SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026 - Newsfile Corp
- 21 days ago - Kaplan Fox Urges ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery to Contact the Firm Before October 5, 2026 - Newsfile Corp
- 26 days ago - ARS Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 4 weeks ago - Kaplan Fox Encourages ARS Pharmaceuticals Inc. (SPRY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on October 5, 2026 - Newsfile Corp
- 4 weeks ago - ARS Pharmaceuticals price target lowered to $15 from $18 at Leerink - TheFly
- 5 weeks ago - ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire